Literature DB >> 22622340

The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations.

Dana M Chase1, Kathryn Osann, Nicole Sepina, Lari Wenzel, Krishnansu S Tewari.   

Abstract

OBJECTIVE: The study aimed to identify sociodemographic and disease-specific factors associated with follow-up in an inner-city multiethnic colposcopy clinic.
MATERIALS AND METHODS: All charts of patients referred to colposcopy clinic for abnormal cervical cytology and/or high-risk human papillomavirus infections to the University of California, Irvine, Colposcopy Clinic in Santa Ana from November 2006 to December 2007 were reviewed. Compliance was defined as at least 1 follow-up evaluation within 3 to 14 months from initial colposcopy appointment. To determine compliance, the following factors were evaluated in a multivariate analysis: race, age, spoken language, insurance status, annual income, marital status, referral cytology, histology, and pregnancy status.
RESULTS: Among the 1,046 scheduled appointments, 50% were attended. Of the patients, 458 with a minimum of 14 months of follow-up were included. The mean (SD) age of these patients was 31.0 (10.7) years. 58% were white and 55% spoke Spanish. A total of 248 patients (54%) had appropriately timed repeat testing, whereas 210 (46%) failed to return within 14 months. In univariate analysis, women who were referred from outside the clinic, single, younger than 40 years, and with self-pay or government-funded insurance were more likely to be noncompliant although this was not statistically significant. In multivariate analysis, referral from outside the clinic, self-pay, or government-funded insurance, Spanish-speaking, and single marital status were all significantly associated with noncompliance. Although cervical intraepithelial neoplasia 2 or 3 was not associated with noncompliance, 45% of women with cervical intraepithelial neoplasia 2 or 3 still did not comply with recommendations.
CONCLUSIONS: This inner-city clinic is perhaps successful at maintaining compliance for women at highest risk for cervical cancer when the triage originates from within the clinic and when the patient is married, English-speaking, and privately insured. However, reasons for those patients at highest risk for noncompliance in this clinic may need to be better characterized.

Entities:  

Mesh:

Year:  2012        PMID: 22622340      PMCID: PMC4293035          DOI: 10.1097/LGT.0b013e318249640f

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  31 in total

1.  Attitudes toward cervical cancer screening among Muslim women: a pilot study.

Authors:  Mina Matin; Samuel LeBaron
Journal:  Women Health       Date:  2004

2.  Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity.

Authors:  Jill Barnholtz-Sloan; Nitin Patel; Dana Rollison; Karl Kortepeter; Jill MacKinnon; Anna Giuliano
Journal:  Cancer Causes Control       Date:  2009-03-01       Impact factor: 2.506

3.  Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class, and hospital type.

Authors:  J Mandelblatt; H Andrews; J Kerner; A Zauber; W Burnett
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

4.  Direct visual inspection of the cervix for the detection of premalignant lesions.

Authors:  Amr El-Shalakany; Sabry S Hassan; Essam Ammar; Mohammad A Ibrahim; Magda Abdel Salam; Mohammad Farid
Journal:  J Low Genit Tract Dis       Date:  2004-01       Impact factor: 1.925

5.  Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.

Authors:  Robert G Pretorius; Pat Peterson; Faramarz Azizi; Raoul J Burchette
Journal:  Am J Obstet Gynecol       Date:  2006-11       Impact factor: 8.661

6.  Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma.

Authors:  Nicolas Wentzensen; Mark Schiffman; S Terence Dunn; Rosemary E Zuna; Joan Walker; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Jose Jeronimo; Michael A Gold; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

Review 7.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

Review 8.  2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.

Authors:  Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

Review 9.  The epidemiology of cervical carcinogenesis.

Authors:  M H Schiffman; L A Brinton
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

10.  Sociodemographic factors associated with high-risk human papillomavirus infection.

Authors:  Jessica A Kahn; Dongmei Lan; Robert S Kahn
Journal:  Obstet Gynecol       Date:  2007-07       Impact factor: 7.661

View more
  3 in total

1.  Predictors of adherence to follow-up recommendations after an abnormal Pap smear among underserved inner-city women.

Authors:  Suzanne M Miller; Erin K Tagai; Kuang-Yi Wen; Minsun Lee; Siu-Kuen Azor Hui; Deirdre Kurtz; John Scarpato; Enrique Hernandez
Journal:  Patient Educ Couns       Date:  2017-01-31

2.  Tailored telephone counseling to improve adherence to follow-up regimens after an abnormal pap smear among minority, underserved women.

Authors:  Suzanne M Miller; Siu-kuen Azor Hui; Kuang-Yi Wen; John Scarpato; Fang Zhu; Joanne Buzaglo; Enrique E Hernandez
Journal:  Patient Educ Couns       Date:  2013-08-19

Review 3.  Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer.

Authors:  Rebecca Luckett; Sarah Feldman
Journal:  Hum Vaccin Immunother       Date:  2015-11-20       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.